MedPath
EMA Product

EndolucinBeta

Product approved by European Medicines Agency (EU)

Basic Information

EndolucinBeta

Regulatory Information

EMEA/H/C/003999

Authorised

July 6, 2016

10

February 16, 2021

Company Information

Germany

Lichtenbergstrasse 1, Garching b. Muenchen, Bayern, 85748

ITM Medical Isotopes GmbH

Active Substances Detail

Detailed Information

Therapeutic Indication

### Therapeutic indication EndolucinBeta is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with Lutetium (177Lu) chloride.

Overview Summary

EndolucinBeta contains the radioactive compound lutetium (177Lu) chloride and is used for radiolabelling other medicines. Radiolabelling is a technique for tagging (or labelling) medicines with radioactive compounds so they can carry radioactivity to where it is needed in the body, for example the site of a tumour. EndolucinBeta isl to be used to radiolabel medicines that have been specifically developed for use with lutetium (177Lu) chloride.

© Copyright 2025. All Rights Reserved by MedPath